Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial Data reinforces the therapeutic potential and safety profile of HDP-101 in relapsed or refractory multiple myeloma. R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST) Ladenburg, Germany, 3 […]
DT-7012 is a proprietary, differentiated Treg-depleting anti-CCR8 monoclonal antibody Differentiated binding capacities and competitive properties position it as a promising therapeutic to boost anti-tumor immunity, overcoming immunosuppression Strasbourg, France – Montreal, Canada – Boston, United States, October 28, 2025: Domain Therapeutics ( “Domain” or “the Company” ), the GPCR experts harnessing deep receptor biology to develop […]
Recognizes the potential of HDP-101 to address a serious or life-threatening condition with high unmet medical needs Enables more frequent engagement with FDA and eligibility for rolling review to support expedited development and review Ladenburg, Germany, 23 October 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), […]
Exclusive license via Yeda to two Weizmann Institute patent families from Prof. Nir London’s lab, a leader in covalent drug design Site-specific, durable and traceless protein radiolabeling approaches intended to enhance tumor selectivity and retention in radiopharmaceuticals Integration into Actithera’s platform to support design of next-generation radioligand therapies across oncology indications Cambridge, MA and Oslo, […]
Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors Barcelona, […]
